Verve Therapeutics Appoints Allison Dorval, Experienced Financial Executive, as Chief Financial Officer
29 nov. 2021 08h00 HE
|
Verve Therapeutics
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course...
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results
10 nov. 2021 06h30 HE
|
Verve Therapeutics
VERVE-101 Preclinical Data Announced at TIDES 2021 Demonstrated Potent, Durable PCSK9 Protein and LDL-C Reductions, Supporting Planned Clinical Initiation in 2022 New Preclinical Data from ANGPTL3...
Verve Therapeutics Reports Preclinical Data Demonstrating Potent Editing of ANGPTL3 Gene Using Proprietary GalNAc-LNP Delivery Technology in Non-Human Primates
09 nov. 2021 06h30 HE
|
Verve Therapeutics
ANGPTL3 Base Editor Delivered via Internally Developed GalNAc-LNPs Potently Reduced Blood ANGPTL3 Protein by 94-97% in a Novel NHP Model of Homozygous Familial Hypercholesterolemia GalNAc-LNP...
Verve Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit
21 oct. 2021 06h30 HE
|
Verve Therapeutics
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines,...
Verve Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
27 sept. 2021 06h30 HE
|
Verve Therapeutics
CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines,...
Verve Therapeutics Reports New Preclinical Data with VERVE-101 Demonstrating Robust, Durable and Precise Editing of the PCSK9 Gene for the Treatment of Cardiovascular Disease
23 sept. 2021 06h30 HE
|
Verve Therapeutics
Treatment of Non-Human Primates with Clinical Candidate, VERVE-101, Led to Durable Reductions of PCSK9 Protein and Low-density Lipoprotein Cholesterol Comprehensive Off-Target Editing Analysis...
Verve Therapeutics Announces Development of Proprietary GalNAc-LNP Delivery Technology Enabling Efficient In Vivo Liver Delivery of Base Editors
23 sept. 2021 06h30 HE
|
Verve Therapeutics
CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines,...
Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
12 août 2021 06h30 HE
|
Verve Therapeutics
New Preclinical Base Editing Durability Data and Proprietary GalNAc-targeted Lipid Nanoparticle Delivery Technology Data to be Presented at TIDES in September 2021 VERVE-101 IND-Enabling Studies...
Verve Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
21 juin 2021 16h05 HE
|
Verve Therapeutics
CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene...